The estimated Net Worth of Cedric O'gorman is at least $30.6 Тысяча dollars as of 23 May 2023. Cedric gorman owns over 10,000 units of Relmada Therapeutics Inc stock worth over $30,565 and over the last 2 years Cedric sold RLMD stock worth over $0.
Sign up
Cedric gorman RLMD stock SEC Form 4 insiders trading
Cedric has made over 1 trades of the Relmada Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Cedric bought 10,000 units of RLMD stock worth $31,800 on 23 May 2023.
The largest trade Cedric's ever made was buying 10,000 units of Relmada Therapeutics Inc stock on 23 May 2023 worth over $31,800. On average, Cedric trades about 5,000 units every 0 days since 2023. As of 23 May 2023 Cedric still owns at least 10,121 units of Relmada Therapeutics Inc stock.
You can see the complete history of Cedric gorman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cedric gorman's mailing address?
Cedric's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES, FL, 33134.
Insiders trading at Relmada Therapeutics Inc
Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over $1,379,052 worth of Relmada Therapeutics Inc stock and bought 574,305 units worth $1,722,071 . The most active insiders traders include Sergio Traversa, Charles J Casamento и Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $54,221. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth $394,800.
What does Relmada Therapeutics Inc do?
relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
What does Relmada Therapeutics Inc's logo look like?
Complete history of Cedric gorman stock trades at Relmada Therapeutics Inc
Relmada Therapeutics Inc executives and stock owners
Relmada Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sergio Traversa,
Chief Executive Officer, Director -
Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD,
CEO & Director -
Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA,
CEO & Director -
Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph.,
Chief Financial Officer -
Charles Casamento,
Independent Chairman of the Board -
Paul Kelly,
Independent Director -
Maged Shenouda,
Chief Financial Officer -
Charles S. Ence CPA, M.B.A.,
Chief Accounting & Compliance Officer -
Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA,
Chief Financial Officer -
Andrew Ipsum,
IR Contact Officer -
Eric Schmidt,
Independent Director -
John Glasspool,
Independent Director -
Marco Pappagallo,
Acting Chief Medical Officer -
Paolo Manfredi,
Acting Chief Scientific Officer -
Charles Ence,
Chief Accounting Officer, Chief Compliance Officer -
Marc de Somer,
Senior Vice President - Clinical Development -
Thomas Wessel,
Executive Vice President, Head of Research and Development -
John Hixon,
Head of Commercial -
Dr. Richard M. Mangano,
Consultant -
Dr. Marco Pappagallo M.D.,
Chief Medical Officer -
Dr. Marc de Somer M.B.A., M.D., M.P.H., M.Sc.,
Sr. VP of Clinical Devel. -
Gina DiGuglielmo,
VP & Head of Clinical Operations -
Dr. Paolo Manfredi M.D., Ph.D.,
Chief Scientific Officer -
Molly Harper,
Exec. VP of Operations -
Fabiana Fedeli,
Director -
Ottavio V. Vitolo,
Chief Medical Officer -
Chuck Ence,
CA and CO